These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9069553)

  • 61. Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
    Shapiro MA; Sesnie JC; Desaty TM; Griffin TJ; Heifetz CL
    J Antimicrob Chemother; 1998 Mar; 41(3):403-5. PubMed ID: 9578169
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibacterial activity of sparfloxacin against experimental renal infections in mice.
    Georgopoulos A; Feistauer SM; Graninger W; Pfleger S; Georgopoulos M
    Antimicrob Agents Chemother; 1992 Feb; 36(2):505-7. PubMed ID: 1318685
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.
    Meinen JB; McClure JT; Rosin E
    Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Initial clinical experience with clinafloxacin in the treatment of serious infections.
    Tack KJ; McGuire NM; Eiseman IA
    Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
    [No Abstract]   [Full Text] [Related]  

  • 65. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of animal models in evaluation of the quinolones.
    Sande MA; Brooks-Fournier RA; Gerberding JL
    Rev Infect Dis; 1988; 10 Suppl 1():S113-6. PubMed ID: 3279487
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
    Willcox MD
    Clin Exp Optom; 2011 Mar; 94(2):161-8. PubMed ID: 21083760
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Resistance and new antibiotic strategies. New antistaphylococcal antibiotics].
    Bergogne-Bérézin E
    Presse Med; 2000 Dec; 29(37):2023-7. PubMed ID: 11155724
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
    Nord CE
    Infection; 1999; 27(3):166-72. PubMed ID: 10378126
    [No Abstract]   [Full Text] [Related]  

  • 71. Bacterial resistance to fluoroquinolones: mechanisms and patterns.
    Hooper DC
    Adv Exp Med Biol; 1995; 390():49-57. PubMed ID: 8718601
    [No Abstract]   [Full Text] [Related]  

  • 72. Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.
    Shapiro MA; Dever JA; Sesnie JC; VanderRoest SR
    J Antimicrob Chemother; 1997 Feb; 39(2):273-6. PubMed ID: 9069553
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.